-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 21, 2021, Boehringer Ingelheim announced the acquisition of Abexxa Biologics
.
This acquisition will enable Boehringer Ingelheim to gain Abexxa's expertise in targeting cancer-specific proteins located inside cells and expand the range of potential cancer antigen targets
Abexxa focuses on the development of innovative immunotherapies around the intracellular antigens presented by atypical major histocompatibility complex (MHC) class I molecules on cancer cells to directly kill tumors or mediate tumor death through immune regulation
.
Atypical MHC class I molecular complexes have been shown to play an important role in regulating innate and adaptive immune responses
Abexxa's platform can generate highly specific human antibodies against these targets
.
The company has developed specific expertise for the atypical MHC class I molecule HLA-E, which has the potential to affect a wider range of cancer antigens
▲The mechanism of action of antibodies similar to TCR (picture source: reference [2])
Reference materials:
[1] Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches.
[2] UTA's AbeXXa Biologics named one of 40 "Best University Startups 2017" by National Council of Entrepreneurial Tech Transfer.
(The original text has been deleted)